As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall Street's projections, several notable biotechs could see their shares soar in the next 12 months.Of course, it wouldn't be wise to rush to invest in these companies for that reason alone, but it might be worth looking deeper into what the Street considers severely undervalued drugmakers. Read on to learn m ...

ZUG, Switzerland and BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 24th Annual Needham Virtual Healthcare Conference on Tue, April 8 at 12:45 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at ...

A bad combination compounding for biotech So not only were these stocks slammed by the risk-off mentality in the markets ahead of tariffs coming on April 2, but a key resignation at the Federal Drug Administration (FDA) over the weekend raised questions about the speed and willingness of the agency to approve new drug technologies going forward. The double whammy sent these stocks down much more than the market today. Key FDA regulator Marks abruptly leaves Over the weekend, Dr. Peter Marks, who headed the ...

Genomics encompasses the study of a complete set of genes, their work process, and their way of interacting with each other and the environment. While it incorporates elements of genetics, the primary focus is on characterizing all the genes of an organism, rather than individual genes.The evolution of genomics in the last couple of decades to decode diseases has ushered in a revolutionary era in genetic medicine. There have been several breakthroughs in this field, attracting the attention of pharma and bi ...

ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne Bruno, will be stepping down from the Company to pursue external opportunities, effective as of April 11, 2025. "Julie has been an invaluable member of our leadership team over the last six years. Her leadership has been instrumental in successfull ...

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CRSP over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking ...

Group 1: CRISPR Therapeutics - CRISPR Therapeutics' shares have declined by 41% over the past year, primarily due to slow revenue generation from its approved gene-editing therapy, Casgevy, which treats rare blood diseases [2][3] - Casgevy is priced at $2.2 million per treatment and is a one-time curative option, with a significant market opportunity in the U.S., U.K., European Union, and several Middle Eastern countries [5][4] - The company is also developing other gene-editing therapies, including a functional cure for type 1 diabetes and CTX112 for B-cell malignancies, which has received Regenerative Medicine Advanced Therapy designation [6][7] Group 2: Merck - Merck's revenue for the last year was $64.2 billion, a 7% increase from 2023, with Keytruda generating $29.5 billion, accounting for approximately 46% of total revenue [9][12] - Competition from ivonescimab, which performed better than Keytruda in a clinical trial, poses a risk to Keytruda's market share, especially as its patent will expire in 2028 [8][9] - Merck is proactively extending Keytruda's patent life and developing new medicines, including LM-299 and HS-10535, while maintaining a strong dividend yield of over 3.4% [10][11][12]

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock might soar as investors bet on the company's cutting-edge technology through its development stages -- and the stock could continue to gain after that company moves into the product commercialization stage.Once biotech products reach the marketplace, biotech companies benefit just like pharma companies from the following: Patients need their treatments regardless of the general economic ...

Shares of CRISPR Therapeutics (CRSP) closed at $40.97 on Tuesday, close to their 52-week low of $36.52.This decline in CRSP stock is mainly due to a lack of pipeline updates, which is not sitting well with investors. Also, the company is yet to record revenues from the sales of its sole-marketed product Casgevy, despite it being approved in early 2024.Shares of CRISPR Therapeutics have plunged 43% in the past year compared with the industry’s 7% decline, as seen in the chart below. The stock has also underp ...

Core Insights - The Motley Fool aims to enhance the financial well-being of individuals by providing investment solutions and market analysis [1] Company Overview - Founded in 1993, The Motley Fool is a financial services company focused on making the world smarter, happier, and richer [1] - The company reaches millions of people monthly through various platforms, including premium investing solutions, free guidance, and market analysis on Fool.com [1] - The Motley Fool also produces top-rated podcasts and operates a non-profit organization, The Motley Fool Foundation [1]